Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Jun;33(6):617–621. doi: 10.1111/j.1365-2125.1992.tb04090.x

The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.

R Pöyhiä 1, T Seppälä 1, K T Olkkola 1, E Kalso 1
PMCID: PMC1381353  PMID: 1389934

Abstract

1. The pharmacokinetics and metabolism of oxycodone were studied in nine healthy young volunteers in a cross-over study. Each subject received oxycodone chloride once intramuscularly (0.14 mg kg-1) and twice orally (0.28 mg kg-1) at intervals of 2 weeks. A double-blind randomized pretreatment with amitriptyline (10-50 mg a day) or placebo was given prior to oral oxycodone. 2. The concentrations of oxycodone, noroxycodone and oxymorphone in plasma and the 24 h urine recoveries of their conjugated and unconjugated forms were measured by gas chromatography. 3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively. The median tmax of oxycodone was 1 h in all groups. The bioavailability of oral relative to i.m. oxycodone was 60%. The mean renal clearance of oxycodone was 0.07-0.08 l min-1. The kinetics of oxycodone were unaffected by amitriptyline. 4. The mean ratio of the AUC(0.24 h) values of unconjugated noroxycodone to oxycodone was 0.45 after i.m. oxycodone and 0.6-0.8 after oral oxycodone. Plasma oxymorphone concentrations were below the limit of the assay. Eight to 14% of the dose of oxycodone was excreted in the urine as unconjugated and conjugated oxycodone over 24 h. Oxymorphone was excreted mainly as a conjugate whereas noroxycodone was recovered mostly in an unconjugated form.

Full text

PDF
617

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beaver W. T., Wallenstein S. L., Rogers A., Houde R. W. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther. 1978 Oct;207(1):101–108. [PubMed] [Google Scholar]
  2. Brunk S. F., Delle M. Morphine metabolism in man. Clin Pharmacol Ther. 1974 Jul;16(1):51–57. doi: 10.1002/cpt1974161part151. [DOI] [PubMed] [Google Scholar]
  3. Glare P. A., Walsh T. D. Clinical pharmacokinetics of morphine. Ther Drug Monit. 1991 Jan;13(1):1–23. doi: 10.1097/00007691-199101000-00001. [DOI] [PubMed] [Google Scholar]
  4. Hoskin P. J., Hanks G. W., Aherne G. W., Chapman D., Littleton P., Filshie J. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol. 1989 Apr;27(4):499–505. doi: 10.1111/j.1365-2125.1989.tb05399.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ishida T., Oguri K., Yoshimura H. Determination of oxycodone metabolites in urines and feces of several mammalian species. J Pharmacobiodyn. 1982 Jul;5(7):521–525. doi: 10.1248/bpb1978.5.521. [DOI] [PubMed] [Google Scholar]
  6. Ishida T., Oguri K., Yoshimura H. Isolation and identification of urinary metabolites of oxycodone in rabbits. Drug Metab Dispos. 1979 May-Jun;7(3):162–165. [PubMed] [Google Scholar]
  7. Kalso E., Pöyhiä R., Onnela P., Linko K., Tigerstedt I., Tammisto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand. 1991 Oct;35(7):642–646. doi: 10.1111/j.1399-6576.1991.tb03364.x. [DOI] [PubMed] [Google Scholar]
  8. Kalso E., Vainio A., Mattila M. J., Rosenberg P. H., Seppälä T. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol. 1990 Oct;67(4):322–328. doi: 10.1111/j.1600-0773.1990.tb00838.x. [DOI] [PubMed] [Google Scholar]
  9. Kalso E., Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990 May;47(5):639–646. doi: 10.1038/clpt.1990.85. [DOI] [PubMed] [Google Scholar]
  10. Laitinen L., Kanto J., Vapaavuori M., Viljanen M. K. Morphine concentrations in plasma after intramuscular administration. Br J Anaesth. 1975 Dec;47(12):1265–1267. doi: 10.1093/bja/47.12.1265. [DOI] [PubMed] [Google Scholar]
  11. Mather L. E., Lindop M. J., Tucker G. T., Pflug A. E. Pethidine revisited: plasma concentrations and effects after intramuscular injection. Br J Anaesth. 1975 Dec;47(12):1269–1275. doi: 10.1093/bja/47.12.1269. [DOI] [PubMed] [Google Scholar]
  12. Mather L. E., Tucker G. T. Systemic availability of orally administered meperidine. Clin Pharmacol Ther. 1976 Nov;20(5):535–540. doi: 10.1002/cpt1976205535. [DOI] [PubMed] [Google Scholar]
  13. Osborne R., Joel S., Trew D., Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet. 1988 Apr 9;1(8589):828–828. doi: 10.1016/s0140-6736(88)91691-1. [DOI] [PubMed] [Google Scholar]
  14. Osborne R., Joel S., Trew D., Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990 Jan;47(1):12–19. doi: 10.1038/clpt.1990.2. [DOI] [PubMed] [Google Scholar]
  15. Pöyhiä R., Olkkola K. T., Seppälä T., Kalso E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol. 1991 Oct;32(4):516–518. doi: 10.1111/j.1365-2125.1991.tb03942.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shimomura K., Kamata O., Ueki S., Ida S., Oguri K. Analgesic effect of morphine glucuronides. Tohoku J Exp Med. 1971 Sep;105(1):45–52. doi: 10.1620/tjem.105.45. [DOI] [PubMed] [Google Scholar]
  17. Stanski D. R., Greenblatt D. J., Lowenstein E. Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther. 1978 Jul;24(1):52–59. doi: 10.1002/cpt197824152. [DOI] [PubMed] [Google Scholar]
  18. Säwe J., Dahlström B., Paalzow L., Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther. 1981 Nov;30(5):629–635. doi: 10.1038/clpt.1981.214. [DOI] [PubMed] [Google Scholar]
  19. Takki S., Tammisto T. A comparison of pethidine, piritramide and oxycodone in patients with pain following cholecystectomy. Anaesthesist. 1973 Apr;22(4):162–166. [PubMed] [Google Scholar]
  20. Weinstein S. H., Gaylord J. C. Determination of oxycodone in plasma and identification of a major metabolite. J Pharm Sci. 1979 Apr;68(4):527–528. doi: 10.1002/jps.2600680441. [DOI] [PubMed] [Google Scholar]
  21. Yue Q., von Bahr C., Odar-Cederlöf I., Säwe J. Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol. 1990 Mar;66(3):221–226. doi: 10.1111/j.1600-0773.1990.tb00737.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES